The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I remember when these were 20p. RNS like this are very rare. Should be triple this Imo.
Moving up ..
Wow. Really motoring now.
So The Swiss Company are paying up to $160.5M for SFX-01 solely for the Global rights in Neurodevelopmental disorders & Schizophrenia.
This is an EXPANSION of its lead asset.
EVGEN retains THE GLOBAL RIGHTS For ALL OTHER INDICATIONS.
I see you had a very good RNS this morning and people who know the share really believe that this has a lot of positive value. I’ve bought £2k’s worth at 4.57, I’ll look at it this evening. Good luck.
4.7 ask now ;-)
Hope everyone got their top ups in.
Could buy at 4.37. Now could well see an attack on 5p. Amazing share
The MM's have been dropping the bid to scare PIs to sell. The whole of the time it's been at NT to buy. I'm not going to try trade this one. I feel I've stumbled on an incredible investment share. I don't really care where this goes over the short term. I'm seeing this is a mid term hold for me now. Ps I was very lucky to bag some at 4.15p today
Bounced and now heading back up ;-)
doesn't matter where it's going to be next year. right now folk are getting spiked. they'll be the ones talking about 'the future' and preparing for being long term holders.
that's fine but you have to accept that the rise won't nec. keep going until it reaches 15-20p. as long as you're good with the drops too... all is good.
gla.
The more I look into this company the more excited I am. The pipeline looks incredibly strong, and partnering up with some world class companies. This could be a mega multi bagger over the next year
https://www.proactiveinvestors.co.uk/companies/news/985007/evgen-pharma-talks-through-clinical-milestones-and-financial-results-from-its-2022-full-year-report-985007.html?rel=scroll
Excellent potential even before today's announcement.
No lupus agree, patience wait for valuation 15/20p it's up trajectory to realise at least £50 million market cap...imo
Easyp,
Patience is a virtue ..
Lot’s to look forward to in 2023 .
Shares in Evgen Pharma PLC rose 44% in early trading Monday after the company said that it has secured a licensing deal for SFX-01 for up to $160.5 million with Stalicla SA.
Shares in Evgen at 0738 GMT were up 1.25 pence at 4.10 pence.
The drug development company said it has licensed the global rights for SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla.
Total milestones of $160.5 million relate to the first neurodevelopmental disorder indication under the license. Royalties payable to Evgen on sales are in the low-to-medium double-digit range, it said.
Yep. They had £9 mill cash 6 months ago. Now this.
Should be cracking 10p over next few days imo
Licensing deal of $160 million for Sfx001 ,it was well oversold for a year....they have cash due to the rights issue at 8p last year..market cap of £12 million is a joke after today's announcement....expect at least 15p
Once early traders have moved on. Steady rise to close gla x
Friday it hit its year low of 2.85 so anyone who bought in then has made some decent money so I don’t blame them top slicing.
Readers should note that EVG are presenting on the “investormeetcompany” platform at 1pm on this Wednesday 12th Oct.
Should be a positive session with todays excellent news etc to discuss the details.
Looking back over the charts it looks like people have been selling it relentlessly maybe even shorting it through CFD’s so it may slow down once shortcovering is done. It’s now up to management to keep interest alive
5p ask
however with small Bio technology companies the problem is when investors realise that this is a long term investment, sp will drop as traders will sell out.
Rns good but the time table for phase 1 is too far way.
then phase 2
phase 3 etc.......
10p today? Very possible imo
Maybe.....but I am still in the red even after today's rise as I bought at 6p.
Fortunately, I averaged down buying at 3.65p so my losses on paper manageable.
Later this week when froth has died off EVG I will buy some more as the news is also imo transformational.